A systematic review of antiproton radiotherapy by Martin-Immanuel Bittner et al.
REVIEW ARTICLE
published: 16 January 2014
doi: 10.3389/fphy.2013.00037
A systematic review of antiproton radiotherapy
Martin-Immanuel Bittner1*, Anca-Ligia Grosu1, Nicole Wiedenmann1 and Jan J. Wilkens2
1 Department of Radiation Oncology, University Medical Center Freiburg, Freiburg, Germany
2 Department of Radiation Oncology, Klinikum Rechts der Isar, Technische Universität München, München, Germany
Edited by:
Jaakko O. Nieminen, Aalto
University, Finland
Reviewed by:
Otto Muzik, Wayne State University,
USA
Edite Figueiras, Tampere University
of Technology, Finland
Jonathan O. De Xivry, Université
Catholique de Louvain, Belgium
*Correspondence:
Martin-Immanuel Bittner,
Department of Radiation Oncology,
University Medical Center Freiburg,
Robert-Koch-Str. 3, D-79106
Freiburg, Germany
e-mail: martin-immanuel.bittner@
uniklinik-freiburg.de
Antiprotons have been proposed as possible particles for radiotherapy; over the past years,
the renewed interest in the potential biomedical relevance led to an increased research
activity. It is the aim of this review to deliver a comprehensive overview regarding the
evidence accumulated so far, analysing the background and depicting the current status
of antiprotons in radiotherapy. A literature search has been conducted, including major
scientific and commercial databases. All articles and a number of relevant conference
abstracts published in the respective field have been included in this systematic review.
The physical basis of antiproton radiotherapy is complex; however, the characterization of
the energy deposition profile supports its potential use in radiotherapy. Also the dosimetry
improved considerably over the past few years. Regarding the biological properties, data
on the effects on cells are presented; however, definite conclusions regarding the relative
biological effectiveness cannot be made at the moment and radiobiological evidence of
enhanced effectiveness remains scarce. There is new evidence supporting the potential
imaging properties, for example for online dose verification. Clinical settings which might
profit from the use of antiprotons have been further tracked. Judging from the evidence
available so far, clinical constellations requiring optimal sparing in the entrance region of
the beam and re-irradiations might profit most from antiproton radiotherapy. While several
open questions remain to be answered, first steps toward a thorough characterization of
this interesting modality have been made.
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INTRODUCTION
Radiotherapy aims at controlling tumors by delivering sufficiently
high doses to achieve a high probability of killing all tumor cells
while at the same time not harming adjacent tissues. The modal-
ities mostly used for irradiation are photon and electron beams.
Over the past decades, proton therapy—as a form of particle ther-
apy with particles heavier than electrons—has evolved as another
beam modality with increasing availability [1]. In addition, sev-
eral other particles have been or are currently being assessed,
such as pions, neutrons, carbon ions or other heavy particles [2].
Another modality, which has been proposed as possibly supe-
rior to other existing and developing therapies, is antiproton
radiotherapy [3, 4]. However, the potential advantages and disad-
vantages of antiproton radiotherapy have been subject to ongoing
debate.
There are currently only very few facilities worldwide where
antiprotons can be produced. The most advanced currently active
facility is located at CERN (Geneva, Switzerland). The antipro-
ton production at Fermilab (Batavia, USA) has stopped after
closure of the Tevatron in 2011. In general, the production of
antiprotons is a very costly and time-consuming process requiring
immense investments in special facilities and their maintenance
[5]. In addition, the current antiproton fluence rates achievable
are relatively low and require a long time to build up relevant
(>1 Gy) doses [6–9]; the experimental conditions are still not
suitable for in vivo experiments [10]. The current flux at the
CERN facility is 3 × 107 antiprotons every 90 s; however, 4 × 1011
antiprotons are needed to deliver a dose of 20 Gy to 100 cm3
[11]. Considering these technological (and economic) issues, it
can be stated that antiproton radiotherapy in any case will only be
available for very special indications and certainly not in the near
future. However, new sites to be opened like the FAIR project at
the GSI (Darmstadt, Germany), might offer the potential to study
clinical implications in more detail over the next years.
Antiproton radiotherapy has first been proposed in 1982, and
in 2008 the first and only detailed review [12] on antiproton
radiotherapy was published so far. However, within the past
6 years, numerous new articles and abstracts have been pub-
lished. Therefore, this review aims at giving an independent,
comprehensive overview regarding the current state of antiproton
radiotherapy research. This is deemed necessary when taking into
account the renewed interest in this modality. In the course of this
article, the physical and biological basis as well as the latest find-
ings will be discussed, while also summarizing and re-examining
possible clinical implications: primarily in therapy, but also in
imaging, taking advantage of the particle spectrum coming into
existence during the annihilation process.
METHODS OF LITERATURE REVIEW
A literature review was performed between October 2012 and
April 2013 using scientific and medical as well as publishers’
databases: PubMed/Medline, BIOSIS, DAHTA, EMBASE, EBSCO
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Host, OvidSP, Elsevier ScienceDirect, SciSearch, Thomson
Reuters (formerly ISI) Web of Knowledge, Scopus, gms, Thieme,
and Karger.
In addition, an open internet search using the most com-
mon web search engines (google.com and scholar.google.com,
yahoo.com, bing.com) was done. Keywords included antiproton,
antiproton therapy, antiproton radiotherapy, antiproton radia-
tion therapy and antiproton imaging.
During the course of the review process, the reference lists of
all articles included were also hand searched to detect any further
articles or abstracts potentially relevant. However, master theses
or doctoral theses were not included.
In the end, this systematic review was based on one compre-
hensive review article, one editorial, one status report and 37
original articles and/or conference abstracts specifically address-
ing the biomedical perspectives of antiproton beams. To our best
knowledge this is the first review since 2008 covering all existing
and accessible scientific works in this field and summarizing and
reviewing them. In addition, several background articles (e.g.,
regarding hadron therapy and range verification as well as related
topics), were also included in writing this review. We therefore
deem our work the first systematic review of the evidence on
antiproton radiotherapy collected so far, to our best knowledge
based on all articles as well as most abstracts available.
CURRENT STATUS OF RESEARCH
PHYSICAL ASPECTS
Antiprotons are the antimatter counterpart of protons. This
means that these particles share the same characteristics (for
example the same mass), except for an opposite charge.
Antimatter particles annihilate with their matter counterparts by
liberating the energy corresponding to their respective masses.
Thus, energy deposition consists of two components: stopping
energy corresponding to the complete loss of kinetic energy until
coming to rest (according to Bethe-Bloch), which is shared by
protons, antiprotons and other particles, and annihilation energy,
which is an exclusive feature of antimatter particles and will be
discussed below. The stopping energies, however, are given for a
specific kinetic energy and range and thus have to be compared
using the same values for different particles.
As for other particle beams, there are certain characteristics
which differ from the clinically more common photon beams.
These include the beam profile, which forms a Bragg peak, and
the secondary particles or fragments which play a role in the
biological effects and will be elaborated on.
A biomedical application of antimatter which is relatively
widespread is positron emission tomography, which involves
detecting the 511 keV photons characteristically emitted when a
positron and its counterpart, the electron, annihilate.
The annihilation energy of an antiproton and a proton on the
other hand is much higher, amounting to 1.88 GeV. This energy is
distributed among a variety of annihilation particles which either
emerge from the annihilation itself or from reactions with nearby
atoms. The most important groups of particles are charged and
uncharged pions (together around 80% of the energy), neutrons,
photons, heavy charged particles (ions of various nuclear charge
andmass) and a small amount of other particles such as electrons,
kaons and neutrinos [4, 13]. Pions and kaons belong to the fam-
ily of mesons, which are hadrons (like protons and neutrons), but
do only consist of two instead of three quarks. They have a mass,
but are short-lived. In contrast, neutrinos are leptons, practically
massless and hardly interacting with othermatter. See also Table 1
for an overview of particles important in this context. This variety
of particles can further be discriminated by half-lives, interaction
patterns etc. However, it is important to note that the major bio-
logical effects in the target are due to the heavy particles with their
high linear energy transfer (LET), although the exact composition
of these particles is unknown [12, 14]. Most other particles leave
the body without further interactions. Some particles, however,
do interact in the body outside the target. In this regard, special
attention has to be paid to neutrons, because of their relatively
high biological effectiveness [6, 15]. See also Figure 1 for an illus-
tration of the energies and respective particle species deposited in
certain volumes within and outside of the body.
When considering the diversity of the annihilation products, it
is important to know how much energy will be deposited locally,
i.e., in the target volume. The estimations for this proportion var-
ied between less than 30MeV [16] and up to 150MeV [4]. The
latest experimental data and simulations point toward 30MeV
being deposited in the immediate vicinity of the annihilation [13].
This amount of energy increases with increasing field size, due
to more secondary particles coming to rest within this increased
radius; on the other hand, increasing field sizes also increase the
amount of secondary particles coming to rest in other parts of the
body, hereby increasing the dose halo [13].
Dosimetry in the mixed particle field of antiproton anni-
hilation is generally difficult [17]. The latest studies report of
advanced (relative) dose measurements using ionization cham-
bers [18], because earlier measurements with thermoluminescent
devices and radiochromic films were not promising due to the
lack of models linking detector responses to actual dose val-
ues [12]. Using alanine detectors for (absolute) dosimetry might
be another option, both for the mixed spectrum peak region
and the plateau [19]. For beam monitoring (also in a possible
clinical setting), monolithic active pixel sensors made of crys-
talline silicon have been proposed and shown first promising
results [20, 21]. A detailed description of currently employed
sensor systems (and the set-up of cell irradiation experiments)
was given by Sellner et al. [21]. It has to be highlighted
that adequate dosimetry is also very important to be able to
define relative biological effectiveness (RBE) values in preclinical
studies.
In addition, in-flight processes have to be distinguished from
at-rest processes. In flight, antiprotons are very comparable to
protons [18]. They do interact slightly more, in particular by
in-flight annihilation events. Originally thought to be a rather
rare event [4, 16] in fact it seems to play a non-negligible role,
especially at higher beam energies [13]. In-flight annihilation is
becoming more important when the normal tissue the beam has
to transverse before entering the target volume increases; for a
planning target volume (PTV) in a depth of 10 cm, a loss of 25%
of the antiprotons has been calculated [22]—which is, however,
still less than the loss of primary carbon ions due to fragmentation
in a corresponding setting with a carbon ion beam.
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Table 1 | Overview of important particles involved in antiproton radiotherapy.
Particle [4, 13] Type and structure Average number of
particles per
annihilation event [13]*
Average energy
distribution per
event [13]*
Range in tissue
[4, 9, 13, 39]
Comment
Antiproton Hadron—Baryon—3
antiquarks
100% =
1.88GeV
Depending on
beam energy
Annihilating particle
Proton Hadron—Baryon—3
quarks
1.0 4% mm to m
Neutron Hadron—Baryon—3
quarks
1.1 4.8% mm to m
Pion (charged) Hadron—Meson—2
quarks
2.7 50.2 % >1m Few interactions
Pion (uncharged) Hadron—Meson—2
quarks
1.7 33.1% Few mm Decay into two photons
Kaon Hadron—Meson—2
quarks
<0.1 <1%
Electron Lepton <0.1 ∼1% mm to m
Neutrino Lepton <1% >1m Hardly no interactions
Heavy particles Varies 0.9 or more ∼1% Few mm Important determinant
of biological effective-
ness
Photon Boson 0.7 6.3% mm to m
*for a 120MeV beam, annihilation at rest, in water.
When slowing down and coming to rest, the antiprotons even-
tually annihilate on a matter particle—the higher the mass, the
more probable this event is [12]. The depth of the majority of the
annihilation events, i.e., the length of the distance in the body, is
subject to the energy of the antiproton beam and can be delin-
eated very sharply, forming a Bragg peak. The depth-dose curve
in water showed the antiproton Bragg peak being twofold higher
compared to a proton beam of the same size and energy while
at the same time showing only a slight elevation along the entry
region [18]. A spread-out Bragg peak (SOBP) can be formed by
variation of the beam energy, thereby covering a potential target
volume.
When spreading out the beam, a number of parameters
change. As mentioned above, the number of secondary particles
increases, which is also the reason for the dose halo and the lat-
eral penumbra to increase. In addition, it is known from other
particles that when broadening the peak or modulation width,
the difference in the RBE between peak and plateau (i.e., entrance
region) will be reduced [13, 23, 24]. However, for antiprotons the
interactions between RBE, LET and beam physics and the influ-
ence of changes on the dose distribution and the biological effects
are only poorly characterized so far.
BIOLOGICAL ASPECTS
Considerations regarding potential radiobiological advantages of
antiprotons were primarily based on the increased energy deposi-
tion (see “Physical aspects”) and on the heavy, high LET particles
causing damage in the immediate vicinity of the annihilation
point; a low oxygen enhancement ratio has also been attributed
[25], but stands without experimental evidence.
A number of experiments with V79 Chinese hamster cells
[7, 11, 26, 27] have been administered at the CERN antiproton
facility in Geneva, Switzerland. The first experiments suffered
from the lacking possibility to adequately consider the physi-
cal depth-dose distribution of the antiproton beam. The later
experiments, however, revealed important information about the
biological effects of antiproton beams. Using clonogenic survival
and Comet assays, it has been shown that the dose fall-off behind
a pristine Bragg peak is very sharp [11]: Within few millimetres,
the Comet assay returns to baseline values and the clonogenic
survival returns to 90%. However, it has to be annotated that
peripheral damage due to more long-range particles such as neu-
trons has not been analyzed in this experimental set-up with
sampling being restricted to approximately 30mm distance from
the irradiation peak. Due to the challenges in dosimetry, RBE val-
ues could only be estimated partly using values calculated through
simulations and after implementing a quantity, defined as the
ratio of fluences rather than doses, thereby dispensing of the need
to assess the absolute dose [7].Whenmaking several assumptions,
this allows an estimate of the RBE, because fluence and dose are
directly proportional. Following this approach, the RBE estimate
for antiprotons in a 2.5mm SOBP for a 46.7MeV pulsed beam
was reported to be 2.25 [7], with a peak-to-plateau dose ratio of
4, both values roughly twice as high as for protons.
The afore-mentioned assumptions were first that the antipro-
ton RBE in the plateau (i.e., the in-flight RBE) is equal to that of
protons [28, 29] and therefore 1 [30] and second that the Monte
Carlo simulation of the antiproton dose ratio is accurate enough.
However, the LET influences the RBE and therefore also has
to be addressed. This explains that once the LET was known,
RBE values from other experiments had to be re-evaluated. For
the Bragg peak, the LET has recently been found to be around
19 keV/µm [28]; it has been indicated that the RBE in the plateau
can be assumed to be around 1.2–1.3, instead of the 1 originally
www.frontiersin.org January 2014 | Volume 1 | Article 37 | 3
Bittner et al. Antiproton radiotherapy
FIGURE 1 | Energy deposition (particle rest mass and kinetic energy of
the antiproton) in relation to particle type and location relative to the
annihilation point (in percent) [13]. The circle denotes the region within
5mm of the annihilation point, the inner rectangle the planning target
volume (10 × 10 × 10 cm3) and the outer rectangle the water phantom
(50 × 50 × 150 cm3). With increasing distance from the point of
annihilation, the contribution towards energy deposition of protons, pions
and electrons increases, whilst the proportion of heavy particles decreases.
expected. This means the RBE in the peak region, which is
expressed in relation to the RBE in the plateau region also had to
be re-estimated: instead of 2.25 expected so far [7], it might rather
be 2.7–3.0 (again, for very small SOBPs) [28]. The accuracy of the
estimates for the RBE values may be improved when the plans to
re-evaluate all experiments done so far is put into effect [31].
The latest biological experiments exposed human fibroblasts
to antiproton radiation and also analyzed possible bystander
effects [8]: The gamma-H2AX assay, a sensitive method to show
DNA damage appearing as foci, revealed that there was consid-
erable DNA damage in the peak region which appeared to be
qualitatively different from the damage in the plateau. The sec-
ond technique used was a plasmid DNA solution. Different forms
of DNA damage result in different forms of fragments which
can be separated electrophoretically. This revealed a majority of
double-strand and complex breaks caused by antiprotons. Other
samples of cells were not directly irradiated with the antipro-
ton beam but either exposed to secondary particles or exposed
to secondary particles while sharing their medium with irradi-
ated cells. However, no significant effects were found for either
samples. Inconsistent results may in part be due to small sam-
ple sizes and suboptimal experimental conditions, including long
transport times of biological material to and from the laboratory
facilities [8].
Secondary particles generated in the annihilation event can
increase the dose in other parts of the body. Among these par-
ticles, neutrons attracted most attention so far, regarding their
high biological effectiveness. Their measurement is difficult, but
thermoluminescent detectors seem to provide reliable results
for thermal neutron fluence [9]. Bubble detectors have been
used for the measurement of fast neutron fluence, but are of
limited applicability in mixed particle fields [15]. According to
the current understanding, thermal neutrons contribute only
insignificantly to dose outside the target volume [9]. High energy
neutrons, however, do have a significant dose-increasing effect in
distant parts of the body, where the respective organ dose depends
on irradiation field geometry and distance to the target volume
[32, 33]. The equivalent dose has been estimated to be around
60 times higher than for a comparable proton therapy treatment
plan for a cylindrical intracranial target volume of 1 cm diameter
and 1 cm length [33]. However, the delivery technique used is also
supposed to have a substantial influence on this relative increase
[34]. In addition, the dose distributed by neutrons is increas-
ing with the target volume, which has led to the conclusion that
antiprotons in general might only be suitable for irradiating rel-
atively small structures [9]. However, the calculations presented
have to be interpreted cautiously, taking into account that the
adequacy of the currently used weighting factors for secondary
neutrons evolving from proton treatment has also been ques-
tioned [35]. Therefore, at the moment no definite conclusions
on the effects of the secondary neutrons can be drawn. Further
neutron calculations using benchmarked Monte Carlo codes and
stating results according to established ICRP protocols are to be
recommended. The physical dose contributions to other parts of
the body due to pions and photons is similar to the neutron dose,
but because of the low LET, their equivalent dose is supposed to be
significantly smaller [33]. Monte Carlo simulations have recently
been proposed to estimate the peripheral dose to be expected [36].
IMAGING ASPECTS
It has also been suggested that antiprotons could not only be used
for therapy, but also for imaging purposes [3, 37]. Particles evolv-
ing through the annihilation process can be detected when escap-
ing the body and used to define their point of origin by extrapo-
lating the trajectories found when hitting the detectors. The most
intriguing advantage would be the control of the annihilation
position and thus the point of energy delivery. It has also been
proposed to confirm the accuracy of patient-positioning with
antiprotons, directly followed by the application of any charged
particle beam (as long as it is corrected for mass and charge) [37].
However, this proposed calibration still represents a hypotheti-
cal concept. In contrast, the possibility of real-time imaging for
online dose verification during delivery of antiprotons as thera-
peutic modality has further been studied more recently [38–40].
Computer simulations using FLUKA showed that photons and
charged pions could both be used for imaging purposes. These
two annihilation products differ in their characteristics: Photons,
in most cases results of a neutral pion decay happening in the
timescale of less than a femtosecond, scatter to less than 20%
when their energy is higher than 10MeV. In addition, the energy
spectrum offers a prominent peak at 511 keV, which is due to
positron emission by excited nuclei and consecutive annihilation.
Therefore, both photon populations might be feasible for real-
time imaging, noting that the half-life of the excited nuclei is
prolonged, which may result in imaging delayed by a certain fac-
tor of time (around tenths of seconds) [39]. Charged pions, on the
other hand, scatter to a higher degree but are not subject to delay.
Due to scattering, detector positioning and particles stopping in
the patient, the overall efficiency of charged pion-detection in a
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hypothetical sophisticated detector set-up is around 1%, how-
ever this still implies that a fraction of the clinically applied dose
provides sufficient numbers of pions for reliable statistics [38],
as has been hypothesized before [37]. When only the proportion
with kinetic energies higher than 250MeV is selected, the accu-
racy of the location of the annihilation point by extrapolating
the tracks can be improved to up to +/− 1mm. This means
that the exact location of the field and the SOBP may be deter-
mined [38, 39]. The feasibility of another, more realistic detector
set-up has also been studied; especially when assuming a continu-
ous rather than a pulsed antiproton beam currently available, the
accuracy has also been in the range of fewmillimetres, while at the
same time confirming that only a fraction of the therapeutically
administered antiprotons may be needed for imaging [40]. Taken
together, these findings support the notion of an online dose or
range verification during the treatment. However, the literature
data regarding the exact corresponding dose are inconclusive, ren-
dering comparisons with other concepts difficult. These existing
concepts for dose and range verification during proton or car-
bon ion therapy are based onmeasurements of generated positron
emitting nuclei [41, 42] or prompt gamma emission following
nuclear interactions of the primary particles [43].
There is one other possible imaging application of antiprotons:
The term ASTER—antiprotonic stereography—has been coined
to describe the theory and hypothetical technique according to
which antiprotons can also be used to deliver three-dimensional
insights into body structures [37]. There are two different effects
at the basis of this possible application which have led to the
differentiation between ASTER-1 and ASTER-2 [44]. First, the
amount of charged pions coming into existence corresponds with
the number of annihilaton events, thus the density of the respec-
tive material. Reconstructing pion tracks can therefore help to
make assumptions about the density structures of the material
under investigation (ASTER-1). Second, the energy spectrum of
photons emitted during the annihilation can show characteris-
tic properties corresponding with the specific elements capturing
the antiproton. This means, the chemical properties can be inves-
tigated (ASTER-2). It has to be noted that resolution and contrast
are highly dependent on the number of antiprotons used and can
thus be adapted to different tasks. Other advantages include a
very low radiation dose received by the structure and neighboring
tissues—estimated to be lower than a conventional CT dose—
and the possibility to specifically look at certain organs, thereby
sparing other structures. However, this application has not been
further studied yet.
CLINICAL ASPECTS
First proposals for possible clinical indications were rather wide;
the antiproton was seen as a particle superior to all others [4].
With increasing knowledge and understanding, the settings with
possible advantages for antiprotons narrowed. In 2008, the possi-
ble role for antiprotons in radiotherapy has been seen as poten-
tially useful for three groups of patients [12]: First, re-irradiation
of patients with local failure after radiotherapy (taking advan-
tage of a potential sparing of surrounding tissues). Second, small
tumors with organs-at-risk directly neighboring (potentially
improved sparing again). Third, therapy-resistant subvolumes in
a tumor (using the unique radiobiological properties of antipro-
tons with their high RBE). Two years later, a comparison of
antiproton, proton and carbon ion treatment plans in a water
phantom with a PTV of 4 × 4 × 4 cm3 surrounded by 1 × 1 ×
1 cm3 volumes of interest was published [45]. This simulation
revealed that antiprotons have the highest peak-to-plateau ratio,
but do deposit dose beyond the PTV; carbon ions in comparison
have a longer tail, whereas protons deliver no dose at all beyond
the PTV. Outside the PTV, the dose from antiprotons spreads
isotropically whereas carbon ions contain a directional compo-
nent. Antiprotons deliver the lowest dose to the entrance region
and the highest to the PTV, thereby increasing the dose lateral and
beyond the PTV. The mean dose to the whole phantom (exclud-
ing the PTV) for the antiproton beam has been calculated to be
3.6% of the PTV dose, thus being twice as high as for the other
particles. This study used laterally modulated fields to improve
the target coverage. In contrast, Paganetti et al. [13] had used flat
and also larger fields (10 × 10 cm2), which deliver worse results in
terms of target coverage and normal tissue sparing. Since the dose
volume histograms for antiprotons and carbon ions only differed
slightly in the treatment plan comparison by Bassler et al. [45],
it has been concluded that only big differences in the RBE could
compensate for the larger lateral penumbra and the background
dose faced when using antiprotons.
An important question arising in the studies is which field
or target size can be seen as clinically realistic. Most studies
performed so far concentrated on narrow beams. However, the
resulting, very small field sizes tend to underestimate the normal
tissue dose due to secondary particles—a problem, which is much
more pronounced for antiprotons than for protons [13]. Even
when stating that clinically relevant target volumes in antiproton
radiotherapy will rarely reach the dimensions of one liter, it has
to be kept in mind that at least some increase in background dose
has to be expected. A general limitation of most of the studies
performed so far and reported here is the simplistic setting with
cubic water phantoms; this clearly has to be kept in mind when
interpreting the results.
The summarized results can lead to the conclusion that
antiprotons probably offer advantages only in those cases where
the normal tissue in the entrance region is of special impor-
tance. In this context, it has to be highlighted that a typical
peak-to-plateau ratio for a proton beam is around 5–6, for a
carbon ion beam similar, maybe higher (depending on beam
line physics, RBE and other factors) and for an antiproton beam
of the same energy around 9–10 [18, 46, 47]. Please see also
Figure 2 for a schematic illustration of the depth dose profiles of
photon, proton and antiproton beams. This ratio is very favor-
able for antiprotons, but it worsens with increasing beam energy
[13, 48]. Many other characteristics also depend on the beam
energy used: Besides the range and the peak-to-plateau ratio, this
is also true for the in-flight annihilation probability, the secondary
particle spectrum [46] and radiobiological effects [45]. Recently,
energy and intensity modulated treatment plans based on Monte
Carlo simulations have been shown to be feasible for antiprotons
[49].
A possible modification of antiproton radiotherapy has been
proposed by Shmatov [50]: When heavy elements such as
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FIGURE 2 | Schematic display of depth dose profiles of a photon (red),
proton (black) and antiproton beam (blue), with deposited energy
expressed relative to the plateau region [19, 45].
Uranium-238 or Thorium-232 are brought into a tumor, the
biologically effective dose administered with a given antiproton
radiotherapy may be increased by 10% or more. This is explained
with an increased amount of short-range particles due to the
annihilation with the heavy elements and maybe also a reduced
annihilation probability with other nuclei. However, these are
only hypotheses lacking experimental data and not taking into
account clinical complexities such as the effective introduction of
the named substances into the tumor and toxicities potentially
associated with it. In addition, irradiating heavier elements has
also been suggested to lead to a smearing of the irradiated spot
due to an increased neutron yield [51].
Considering the scarcity of (actual and proposed) antipro-
ton producing centers worldwide, it can be hypothesized that
clinical usage of antiprotons will in any case be very restricted.
This is also due to the enormous costs imposed by antipro-
ton production. However, the application of antiprotons may be
facilitated—both from a practical and economic perspective—if
the idea of portable antiproton traps finds its way into practical
use [52, 53]. This technique, based on the trapping of antipro-
tons through electrode potentials (vertical direction) and mag-
netic fields (radial direction) in an electron-cooled low energy
state, might have the potential to render at least some of the
biomedical applications possible in various sites. However, at the
moment these are also mainly theoretical considerations and it is
unknown, if and when this technology could be used in a clinical
setting.
CONCLUSIONS AND OPEN RESEARCH QUESTIONS
When taking into account the simulation results generated over
the past years as well as the latest experimental findings, the fol-
lowing conclusions can be drawn: The peak-to-plateau ratio as
one of the major advantages of the antiproton beam properties is
still a highly valuable feature. However, the lateral penumbra and
increased dose halo compared to other particle beams reduce the
applicability of antiprotons to very few possible indications. There
may be clinical settings—especially when the normal tissue in
the entrance region of the beam is highly radiosensitive—where
antiproton radiotherapy offers special advantages. Possible clini-
cal constellations include the treatment of recurrences, when the
normal tissue has already received the maximum tolerable dose,
and the dose in the entry channel has to be minimized. These
settings have to be further analyzed by generating and compar-
ing treatment plans and the respective dose distributions, based
on assessments of the physical qualities of antiprotons in compar-
ison with the different beam types available so far. In addition,
the possibilities for real-time dose range verification offer a new
feature in contrast to other particle beams which might attract
more attention in the future. Other open questions exist regard-
ing the role of secondary neutrons, which should be investigated
following the appropriate ICRP protocols. Also, the biological
properties of the antiproton beam have to be further character-
ized considering different cell lines and target sizes, as well as the
effects of the medium- and long-range secondary particles.
In particular, the RBE—which depends on correct
dosimetry—has to receive further attention. This has to be
seen as a prerequisite for meaningful treatment planning studies,
because as long as the biological properties are not validated,
antiproton treatment planning cannot be performed. But only
then will it be possible to think about in vivo experiments,
which in turn require new facilities providing adequate fluence
rates. Finally, the most important quantity is the ratio of the
biologically effective dose in the target volume and the biologi-
cally effective dose to the normal tissue. This in turn has to be
evaluated carefully in terms of cell killing (e.g., in the tumor) and
of induction of secondary tumors (in the normal tissue).
Hence, there are still many open questions which need to be
addressed by future research.
Given these uncertainties, no timeframe or schedule for an
implementation into clinical practice can be predicted. However,
research over the past decade did show progress in various—
physical, biological, imaging and clinical—aspects. Therefore, it
can be anticipated that there will be an equaling number of new
results over the next decade. Despite the still unrealistic tech-
nological implementation, the increasing number of pertinent
publications and also patents [54] shows an ongoing academic
interest in antiproton radiotherapy, reinforcing this notion. It is
hoped that further experimental work will provide robust data for
further elucidating the aforementioned questions and will back
up the data generated in the various simulations so far. Only then
will it be possible to draw definite conclusions on the potential
role of antiprotons in clinical practice, and—in consequence—to
evaluate the potential for an implementation of clinical usage.
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